U.S. Markets closed

Mustang Bio, Inc. (MBIO)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.6907+0.0291 (+4.40%)
At close: 04:00PM EDT
0.7270 +0.04 (+5.26%)
After hours: 07:59PM EDT

Mustang Bio, Inc.

377 Plantation Street
1st floor
Worcester, MA 01605
United States
781 652 4500

Full Time Employees102

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael S. Weiss Esq.Exec. Chairman60kN/A1966
Dr. Manuel Litchman M.D.Pres, CEO & Director606.87kN/A1954
Mr. Eliot M. Lurier CPAInterim Chief Financial OfficerN/AN/A1958
Dr. Knut NissChief Technology OfficerN/AN/AN/A
Mr. Matthew Wein J.D.VP & Gen. CounselN/AN/AN/A
Ms. Debra Manning SPHRVP of HRN/AN/AN/A
Ms. Lynn E. BaylessHead of Regulatory AffairsN/AN/AN/A
Mr. Scott Smith M.B.A.Exec. Director and Head of Alliance & Program ManagementN/AN/AN/A
Dr. Bruce Dezube M.D.Sr. VP & Head of Clinical Devel.N/AN/AN/A
Ms. Robyn M. HunterCorp. Sec.N/AN/A1962
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

Corporate Governance

Mustang Bio, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 10. The pillar scores are Audit: 9; Board: 10; Shareholder Rights: 10; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.